Adalimumab in ulcerative colitis – efficacy, safety and optimization in the era of treat-to target

References

• Murch SH, Braegger CP, Walker-Smith JA, et al. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993;34(12):1705–1709. PubMed PMID: 8031350; PubMed Central PMCID: PMC1374467.
   PubMed Web of Science ®Google Scholar
• Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991;32(8):913–917. PubMed PMID: 1885073; PubMed Central PMCID: PMC1378961.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549. DOI:10.1016/S0140-6736(02)08512-4 PubMed PMID: 12047962.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65. DOI:10.1053/j.gastro.2006.11.041 PubMed PMID: 17241859.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357(3):239–250. DOI:10.1056/NEJMoa062897 PubMed PMID: 17634459.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109 e1. DOI:10.1053/j.gastro.2013.06.010 PubMed PMID: 23770005.
   PubMed Web of Science ®Google Scholar
• Mao EJ, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;45(1):3–13. DOI:10.1111/apt.13847 PubMed PMID: 27862107.
   PubMed Web of Science ®Google Scholar
• Vogelaar L, Spijker AV, Van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2009;2:101–109. PubMed PMID: 21694833; PubMed Central PMCID: PMC3108643.
   PubMedGoogle Scholar
• Costa J, Magro F, Caldeira D, et al. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19(10):2098–2110. DOI:10.1097/MIB.0b013e31829936c2 PubMed PMID: 23860567.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323-33; quiz 591. DOI:10.1053/j.gastro.2005.11.030 PubMed PMID: 16472588.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–1239. DOI:10.1136/gut.2006.106781 PubMed PMID: 17299059; PubMed Central PMCID: PMC2701613.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829–838. PubMed PMID: 17470824.
   PubMed Web of Science ®Google Scholar
• Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: a proposed new paradigm for the management of Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(6):1042–50e2. DOI:10.1016/j.cgh.2013.09.006 PubMed PMID: 24036054.
   PubMed Web of Science ®Google Scholar
• Bouguen G, Levesque BG, Pola S, et al. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(6):978–985. DOI:10.1016/j.cgh.2013.11.005 PubMed PMID: 24246770.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. DOI:10.1056/NEJMoa050516 PubMed PMID: 16339095.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. DOI:10.1056/NEJMoa1215734 PubMed PMID: 23964932.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85-95;quiz e14-5. DOI:10.1053/j.gastro.2013.05.048 PubMed PMID: 23735746.
   Web of Science ®Google Scholar
• Van Der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut. 2014;63(1):72–79. DOI:10.1136/gutjnl-2012-303376 PubMed PMID: 23135759.
   PubMed Web of Science ®Google Scholar
• Yu AP, Johnson S, Wang ST, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease. PharmacoEconomics. 2009;27(7):609–621. DOI:10.2165/11312710-000000000-00000 PubMed PMID: 19663531.
   PubMed Web of Science ®Google Scholar
• Yokomizo L, Limketkai B, Park KT. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. BMJ Open Gastroenterol. 2016;3(1):e000093. DOI:10.1136/bmjgast-2016-000093 PubMed PMID: 27195130; PubMed Central PMCID: PMC4860720.
   PubMedGoogle Scholar
• Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol. 1993;94(1):174–181. PubMed PMID: 8403503; PubMed Central PMCID: PMC1534387.
   PubMed Web of Science ®Google Scholar
• Billmeier U, Dieterich W, Neurath MF, et al. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22(42):9300–9313. DOI:10.3748/wjg.v22.i42.9300 PubMed PMID: 27895418; PubMed Central PMCID: PMC5107694.
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/downloads/drugs/developmentapprovalprocess/…/ucm092762.pdf
   Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016;22(8):1999–2015. DOI:10.1097/MIB.0000000000000772 PubMed PMID: 27135483.
   PubMed Web of Science ®Google Scholar
• Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4(10):1248–1254. DOI:10.1016/j.cgh.2006.06.025 PubMed PMID: 16931170.
   PubMed Web of Science ®Google Scholar
• Paul S, Moreau AC, Del Tedesco E, et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(7):1288–1295. DOI:10.1097/MIB.0000000000000037 PubMed PMID: 24831559.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Laclotte C, Roblin X, et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol. 2007;13(16):2328–2332. PubMed PMID: 17511032; PubMed Central PMCID: PMC4147142.
   PubMed Web of Science ®Google Scholar
• Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008;28(8):966–972. DOI:10.1111/j.1365-2036.2008.03811.x PubMed PMID: 18652603.
   PubMed Web of Science ®Google Scholar
• Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009;15(9):1302–1307. DOI:10.1002/ibd.20924 PubMed PMID: 19408340.
   PubMed Web of Science ®Google Scholar
• Gies N, Kroeker KI, Wong K, et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther. 2010;32(4):522–528. DOI:10.1111/j.1365-2036.2010.04380.x PubMed PMID: 20500733.
   PubMed Web of Science ®Google Scholar
• Taxonera C, Estelles J, Fernandez-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33(3):340–348. DOI:10.1111/j.1365-2036.2010.04531.x PubMed PMID: 21133961.
   PubMed Web of Science ®Google Scholar
• McDermott E, Murphy S, Keegan D, et al. Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohn’s Colitis. 2013;7(2):150–153. DOI:10.1016/j.crohns.2012.03.016 PubMed PMID: 22520592.
   Google Scholar
• Italian Group for the Study of Inflammatory Bowel D, Armuzzi A, Biancone L, Daperno M, et al. Adalimumab in active ulcerative colitis: a “real-life” observational study. Dig Liver Dis. 2013;45(9):738–743. DOI:10.1016/j.dld.2013.03.018 PubMed PMID: 23683530.
   PubMedGoogle Scholar
• Garcia-Bosch O, Gisbert JP, Canas-Ventura A, et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohn’s Colitis. 2013;7(9):717–722. DOI:10.1016/j.crohns.2012.10.004 PubMed PMID: 23142005.
   Google Scholar
• Sandborn WJ, Sakuraba A, Wang A, et al. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin. 2016;32(7):1233–1241. DOI:10.1185/03007995.2016.1168290 PubMed PMID: 26986449.
   PubMed Web of Science ®Google Scholar
• Balint A, Farkas K, Palatka K, et al. Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice. J Crohn’s Colitis. 2016;10(1):26–30. DOI:10.1093/ecco-jcc/jjv169 PubMed PMID: 26392413.
   Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–787. DOI:10.1136/gut.2010.221127 PubMed PMID: 21209123.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257-65 e1-3. DOI:10.1053/j.gastro.2011.10.032 PubMed PMID: 22062358.
   Web of Science ®Google Scholar
• Wolf D, D’Haens G, Sandborn WJ, et al. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014;40(5):486–497. DOI:10.1111/apt.12863 PubMed PMID: 25041859.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, D’Haens G, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013;37(2):204–213. DOI:10.1111/apt.12145 PubMed PMID: 23173821.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109(11):1771–1780. DOI:10.1038/ajg.2014.242 PubMed PMID: 25155227; PubMed Central PMCID: PMC4223868.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Lazar A, et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology. 2014;146(1):110–8 e3. DOI:10.1053/j.gastro.2013.09.032 PubMed PMID: 24067881.
   PubMed Web of Science ®Google Scholar
• Singh S, Heien HC, Sangaralingham LR, et al. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2016;43(9):994–1003. DOI:10.1111/apt.13580 PubMed PMID: 26991059; PubMed Central PMCID: PMC4917292.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Cagan A, Cai T, et al. Comparative effectiveness of infliximab and adalimumab in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2016;22(4):880–885. DOI:10.1097/MIB.0000000000000754 PubMed PMID: 26933751; PubMed Central PMCID: PMC4792716.
   PubMed Web of Science ®Google Scholar
• Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39(7):660–671. DOI:10.1111/apt.12644 PubMed PMID: 24506179.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Druyts E, Mills EJ, et al. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohn’s Colitis. 2014;8(7):571–581. DOI:10.1016/j.crohns.2014.01.010 PubMed PMID: 24491514.
   Google Scholar
• Mostafa NM, Eckert D, Pradhan, RS, et al. Exposure-efficacy relationship (ER) for adalimumab during induction phase of treatment of adult patients with moderate to severe ulcerative colitis. Gastroenterology. 2013;144:S-225-S-226.
   Google Scholar
• Ferrante M, Karmiris K, Compernolle G, et al. Efficacy of ADA in patients with UC: restoration of serum levels after dose escalation results in a better long outcome. Stockholm, Sweden: UEGW 2011; 2011.
   Google Scholar
• Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(1):80–4e2. DOI:10.1016/j.cgh.2013.07.010 PubMed PMID: 23891927.
   PubMed Web of Science ®Google Scholar
• Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63(11):1721–1727. DOI:10.1136/gutjnl-2012-304094 PubMed PMID: 24474383; PubMed Central PMCID: PMC4215276.
   PubMed Web of Science ®Google Scholar
• Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(3):531–538. DOI:10.1016/j.cgh.2014.07.055 PubMed PMID: 25117777.
   PubMed Web of Science ®Google Scholar
• Baert F, Vande Casteele N, Tops S, et al. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther. 2014;40(11–12):1324–1332. DOI:10.1111/apt.12968 PubMed PMID: 25277873.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Baert F, Tops S, et al. Post-induction adalimumab concentration is associated with short-term mucosal healing in patients with ulcerative colitis. J Crohn’s Colitis. 2017;11(1):53–59. DOI:10.1093/ecco-jcc/jjw122 PubMed PMID: 27402915.
   Google Scholar
• Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14(4):550–7e2. DOI:10.1016/j.cgh.2015.10.025 PubMed PMID: 26538204.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Jain A, Hauenstein SI, et al. Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2016;22(2):409–415. DOI:10.1097/MIB.0000000000000689 PubMed PMID: 26752470.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn’s disease. Inflamm Bowel Dis. 2009;15(9):1308–1319. DOI:10.1002/ibd.20956 PubMed PMID: 19434735.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14(10):1385–97 e10. DOI:10.1016/j.cgh.2016.04.039 PubMed PMID: 27189910.
   PubMed Web of Science ®Google Scholar
• Reenaers C, Louis E, Belaiche J, et al. Does co-treatment with immunosuppressors improve outcome in patients with Crohn’s disease treated with adalimumab? Aliment Pharmacol Ther. 2012;36(11–12):1040–1048. DOI:10.1111/apt.12076 PubMed PMID: 23061650.
   PubMed Web of Science ®Google Scholar
• Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn’s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2015;13(13):2233-40e1-2; quiz e177-8. DOI:10.1016/j.cgh.2015.06.034 PubMed PMID: 26142167.
   Web of Science ®Google Scholar
• Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014;146(4):941–949. DOI:10.1053/j.gastro.2013.12.025 PubMed PMID: 24361468.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Jharap B, Sandborn WJ, et al. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn’s disease or ulcerative colitis who had failed conventional therapy. Aliment Pharmacol Ther. 2017;45(1):50–62. DOI:10.1111/apt.13838 PubMed PMID: 27883215; PubMed Central PMCID: PMC5157781.
   PubMed Web of Science ®Google Scholar
• Gibson PR, Vaizey C, Black CM, et al. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study. J Crohn’s Colitis. 2014;8(7):598–606. DOI:10.1016/j.crohns.2013.11.017 PubMed PMID: 24345767.
   Google Scholar
• Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374(18):1754–1762. DOI:10.1056/NEJMoa1513248 PubMed PMID: 27144850.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–624. DOI:10.1056/NEJMoa1112168 PubMed PMID: 22894574.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J Crohn’s Colitis. 2013;7(3):213–221. DOI:10.1016/j.crohns.2012.05.015 PubMed PMID: 22704916.
   Google Scholar
• Manginot C, Baumann C, Peyrin-Biroulet L. An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis. Gut. 2015;64(7):1181–1182. DOI:10.1136/gutjnl-2014-308839 PubMed PMID: 25550182.
   PubMed Web of Science ®Google Scholar